Abstract
Background Accumulating studies have suggested associations between peripheral inflammation and neurodegenerative disorders, including Parkinson’s disease (PD).
Objective To evaluate the causal associations between 91 plasma inflammatory proteins and 4 neurodegenerative disorders.
Methods Two-sample Mendelian randomization studies were performed using summary statistics extracted from genome-wide association studies of 91 plasma inflammatory proteins and 4 neurodegenerative disorders.
Results Genetically proxied tumor necrosis factor receptor superfamily member 9 levels were causally associated with reduced risk of PD (odds ratio [OR] = 0.82, 95% confidence interval [CI] = 0.74-0.92, p = 4.18 x 10−4, Bonferroni-corrected p < 0.05 for 91 proteins). Additionally, we identified potential causal associations between the levels of C-C motif chemokine 20 (OR = 1.14, 95%CI = 1.03-1.25, p = 1.29 x 10−2) and Alzheimer’s disease, between levels of leukemia inhibitory factor receptor (OR = 0.91, 95%CI = 0.84-0.98, p = 1.12 x 10−2) and tumor necrosis factor-β (OR = 0.95, 95%CI = 0.93-0.98, p = 1.01 x 10−3) and amyotrophic lateral sclerosis, between levels of adenosine deaminase (OR = 0.81, 95%CI = 0.71-0.94, p = 5.14 x 10−3) and interleukin-18 (OR = 0.81, 95%CI = 0.69-0.96, p = 1.68 x 10−2) and multiple sclerosis.
Conclusions Our study unveils plausible causal associations between circulating inflammatory factors and risk of 4 neurodegenerative disorders. These findings hold promise for promoting risk assessment and prevention of neurodegenerative disorders, meriting further exploration.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants from National Natural Science Foundation of China (Grant No. 81873778, 82071415, and 82060213) and National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (Grant No. NRCTM(SH)-2021-03).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This MR study utilized summary statistics from previous published GWAS with ethical approval by corresponding ethics committee, therefore, additional ethical approval for current study is not required.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data supporting the findings of this study are available from the corresponding author upon reasonable request.